Vividion Secures Exclusive Rights to First-in-Class WRN Inhibitor VVD-214 for MSI-High Cancers
Vividion Therapeutics has secured exclusive worldwide rights to develop VVD-214, the only clinical-stage covalent inhibitor of Werner helicase (WRN) currently in development globally.
Nimbus Therapeutics Initiates First-in-Human Trial of NDI-219216 for MSI-H Tumors Resistant to Standard Therapies
Nimbus Therapeutics has begun dosing patients in a Phase 1/2 clinical trial of NDI-219216, a novel non-covalent Werner syndrome helicase (WRN) inhibitor targeting microsatellite instability-high (MSI-H) solid tumors.
IDEAYA's WRN Inhibitor IDE275 Shows Promise for MSI-H Cancers, Featured in AACR 2025 Oral Presentation
IDEAYA Biosciences and GSK will present promising data on IDE275 (GSK959), a potential best-in-class Werner Helicase inhibitor for MSI-H solid tumors, at AACR 2025's New Drugs on the Horizon series.
Nimbus Therapeutics Names Abbas Kazimi as New CEO in Planned Leadership Transition
Nimbus Therapeutics has appointed Abbas Kazimi as Chief Executive Officer, succeeding Jeb Keiper who steps down after leading the company since 2018 in a planned transition.
Ryvu Therapeutics Advances RVU305 PRMT5 Inhibitor to Preclinical Development; Reports Positive Financials and Clinical Trial Updates
Ryvu Therapeutics is advancing RVU305, a PRMT5 inhibitor, into preclinical development with IND/CTA filing targeted for H2 2025.
Ryvu Therapeutics to Present Promising RVU120 and Synthetic Lethality Data at Major Oncology Conferences
Ryvu Therapeutics will showcase clinical data for RVU120, their CDK8/19 inhibitor, demonstrating efficacy in 15 of 29 evaluable AML and HR-MDS patients, including complete remission in a patient with NPM1 and DNMT3A mutations.